Literature DB >> 11559681

Does cytosine-thymine-guanine (CTG) expansion size predict cardiac events and electrocardiographic progression in myotonic dystrophy?

N R Clarke1, A D Kelion, J Nixon, D Hilton-Jones, J C Forfar.   

Abstract

OBJECTIVE: To assess whether the size of the cytosine-thymine-guanine (CTG) expansion mutation in myotonic dystrophy predicts progression of conduction system disease and cardiac events.
DESIGN: Longitudinal study involving ECG and clinical follow up over (mean (SD)) 4.8 (1.8) and 6.2 (1.9) years, respectively, of patients stratified by CTG expansion size (E0 to E4). PATIENTS: 73 adult patients under annual review in a regional myotonic dystrophy clinic. Patients were grouped into E0/E1 (n = 25), E2 (n = 34), and E3/E4 (n = 14).
RESULTS: The proportion of patients with a QRS complex > 100 ms at baseline increased with the size of the CTG expansion (EO/E1, 4%; E2, 12%; E3/E4, 36%; p = 0.02). This trend was more pronounced at follow up (E0/E1, 4%; E2, 21%; E3/E4, 57%; p = 0.0004). The rate of widening of the QRS complex (ms/year) was similarly related to the size of the mutation (EO/E1, 0.4 (1.3); E2, 1.4 (2.5); E3/E4, 1.5 (1.6); p = 0.04). First degree atrioventricular block was present in 23% of patients at baseline and 34% at follow up, with no significant relation to expansion size. Seven patients suffered a cardiac event during follow up (sudden death in two, permanent pacemaker insertion in three, chronic atrial arrhythmia in two), of whom six were in CTG expansion group E2 or greater. Patients who experienced a cardiac event during follow up had more rapid rates of PR interval increase (9.9 (11.1) v 1.6 (2.9) ms/year; p = 0.008) and a trend to greater QRS complex widening (3.6 (4.5) v 0.9 (1.5) ms/year; p = 0.06) than those who did not.
CONCLUSIONS: Larger CTG expansions are associated with a higher rate of conduction disease progression and a trend to increased risk of cardiac events in myotonic dystrophy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11559681      PMCID: PMC1729946          DOI: 10.1136/heart.86.4.411

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  30 in total

1.  Cardiac abnormalities and cytosine-thymine-guanine trinucleotide repeats in myotonic dystrophy.

Authors:  Y Hayashi; U Ikeda; T Kojo; M Nishinaga; H Miyashita; T Kuroda; K Inoue; M Nishizawa; K Shimada
Journal:  Am Heart J       Date:  1997-08       Impact factor: 4.749

2.  Malignant cardiac involvement in a family with myotonic dystrophy.

Authors:  G Melillo; M P Ruggieri; G Magni; P V Fragola; G Antonini; R Vichi; D Cannata; R R Fenici
Journal:  G Ital Cardiol       Date:  1996-08

3.  Cardiac involvement in myotonic dystrophy.

Authors:  P V Fragola; M Luzi; L Calò; G Antonini; M Borzi; D Frongillo; D Cannata
Journal:  Am J Cardiol       Date:  1994-11-15       Impact factor: 2.778

4.  Relationships among electrophysiological findings and clinical status, heart function, and extent of DNA mutation in myotonic dystrophy.

Authors:  A Lazarus; J Varin; Z Ounnoughene; H Radvanyi; C Junien; J Coste; P Laforet; B Eymard; H M Becane; S Weber; D Duboc
Journal:  Circulation       Date:  1999-03-02       Impact factor: 29.690

Review 5.  Cardiac disease in myotonic dystrophy.

Authors:  M F Phillips; P S Harper
Journal:  Cardiovasc Res       Date:  1997-01       Impact factor: 10.787

6.  Value of the electrocardiogram in determining cardiac events and mortality in myotonic dystrophy.

Authors:  J A Colleran; R J Hawley; E E Pinnow; P F Kokkinos; R D Fletcher
Journal:  Am J Cardiol       Date:  1997-12-01       Impact factor: 2.778

7.  Myotonic dystrophy associated with QT prolongation and torsade de pointes.

Authors:  Y Umeda; U Ikeda; J Yamamoto; H Fukazawa; Y Hayashi; H Fujikawa; K Shimada
Journal:  Clin Cardiol       Date:  1999-02       Impact factor: 2.882

8.  Mechanisms of sustained ventricular tachycardia in myotonic dystrophy: implications for catheter ablation.

Authors:  J L Merino; J R Carmona; I Fernández-Lozano; R Peinado; N Basterra; J A Sobrino
Journal:  Circulation       Date:  1998-08-11       Impact factor: 29.690

9.  Cardiac involvement in a large kindred with myotonic dystrophy. Quantitative assessment and relation to size of CTG repeat expansion.

Authors:  L S Tokgozoglu; T Ashizawa; A Pacifico; R M Armstrong; H F Epstein; W A Zoghbi
Journal:  JAMA       Date:  1995-09-13       Impact factor: 56.272

10.  Larger expansions of the CTG repeat in muscle compared to lymphocytes from patients with myotonic dystrophy.

Authors:  M Anvret; G Ahlberg; U Grandell; B Hedberg; K Johnson; L Edström
Journal:  Hum Mol Genet       Date:  1993-09       Impact factor: 6.150

View more
  12 in total

Review 1.  Myotonic dystrophy and the heart.

Authors:  G Pelargonio; A Dello Russo; T Sanna; G De Martino; F Bellocci
Journal:  Heart       Date:  2002-12       Impact factor: 5.994

2.  QRS prolongation in myotonic muscular dystrophy and diffuse fibrosis on cardiac magnetic resonance.

Authors:  Saman Nazarian; David A Bluemke; Kathryn R Wagner; Menekhem M Zviman; Evrim Turkbey; Brian S Caffo; Monda Shehata; David Edwards; Barbara Butcher; Hugh Calkins; Ronald D Berger; Henry R Halperin; Gordon F Tomaselli
Journal:  Magn Reson Med       Date:  2010-07       Impact factor: 4.668

3.  Endocrine function in 97 patients with myotonic dystrophy type 1.

Authors:  M C Ørngreen; P Arlien-Søborg; M Duno; J M Hertz; J Vissing
Journal:  J Neurol       Date:  2012-02-17       Impact factor: 4.849

4.  Clinical predictors of conduction disease progression in type I myotonic muscular dystrophy.

Authors:  Saman Nazarian; Kathryn R Wagner; Brian S Caffo; Gordon F Tomaselli
Journal:  Pacing Clin Electrophysiol       Date:  2010-10-14       Impact factor: 1.976

5.  Usefulness of clinical and electrocardiographic data for predicting adverse cardiac events in patients with myotonic dystrophy.

Authors:  Robert Breton; Jean Mathieu
Journal:  Can J Cardiol       Date:  2009-02       Impact factor: 5.223

Review 6.  Myotonic Dystrophies: Targeting Therapies for Multisystem Disease.

Authors:  Samantha LoRusso; Benjamin Weiner; W David Arnold
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

7.  Structural and functional cardiac changes in myotonic dystrophy type 1: a cardiovascular magnetic resonance study.

Authors:  Mieke C E Hermans; Catharina G Faber; Sebastiaan C A M Bekkers; Christine E M de Die-Smulders; Monique M Gerrits; Ingemar S J Merkies; Gabriel Snoep; Yigal M Pinto; Simon Schalla
Journal:  J Cardiovasc Magn Reson       Date:  2012-07-24       Impact factor: 5.364

8.  Optical Mapping Approaches on Muscleblind-Like Compound Knockout Mice for Understanding Mechanistic Insights Into Ventricular Arrhythmias in Myotonic Dystrophy.

Authors:  Chung-Chuan Chou; Po-Cheng Chang; Yi-Chia Wei; Kuang-Yung Lee
Journal:  J Am Heart Assoc       Date:  2017-04-17       Impact factor: 5.501

Review 9.  The heart and cardiac pacing in Steinert disease.

Authors:  Gerardo Nigro; Andrea Antonio Papa; Luisa Politano
Journal:  Acta Myol       Date:  2012-10

10.  Symptomatic Trifascicular Block in Steinert's Disease: Is It Too Soon for a Pacemaker?

Authors:  Glenmore Lasam; Roberto Roberti; Gina LaCapra; Roberto Ramirez
Journal:  Case Rep Cardiol       Date:  2016-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.